Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P47898

UPID:
5HT5A_HUMAN

ALTERNATIVE NAMES:
Serotonin receptor 5A

ALTERNATIVE UPACC:
P47898; Q2M2D2

BACKGROUND:
Serotonin receptor 5A, alternatively named 5-hydroxytryptamine receptor 5A, is crucial for serotonin-mediated neurotransmission and hormonal activities. It operates through G protein-mediated pathways, underscoring its significance in cellular signaling. The receptor, identified by the unique identifier P47898, is a key player in the complex network of serotonin regulation, affecting various biological and physiological responses.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of the 5-hydroxytryptamine receptor 5A presents a promising avenue for identifying novel therapeutic approaches. Given its central role in serotonin pathways, targeting this receptor could lead to breakthroughs in treating mental health disorders and beyond.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.